Authors : S. Sai Nitheesh; Bariki Rajasekhar

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/4awkunx8

Scribd : https://tinyurl.com/3t2exhv6

DOI : https://doi.org/10.38124/ijisrt/26May1270

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Repaglinide, a widely used oral antihyperglycemic medication for type 2 diabetes mellitus management, suffers from a transient biological half-life and restricted oral bioavailability, which demands recurrent daily administration. This investigation focuses on engineering a gastroretentive bioadhesive microparticulate vehicle designed to lengthen gastric residence time and facilitate a prolonged drug release pattern.  Methodology: The mucoadhesive microspheres were manufactured utilizing a water-in-oil (W/O) emulsification combined with solvent evaporation. A systematic 23 factorial configuration was utilized to study the impacts of adjusting concentrations of Hydroxypropyl Methylcellulose (HPMC K100M), sodium carboxymethyl cellulose (NaCMC), and Carbopol 934P. Eight separate experimental runs (F1–F8) were produced and systematically characterized regarding micromeritic particle size, percentage recovery yield, encapsulation efficiency, bioadhesive capacity, and cumulative in vitro release behavior.

Keywords : Repaglinide, Mucoadhesive Microspheres, HPMC K100M, Carbopol 934P, Sustained Release, Higuchi Model.

References :

1. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1):S20-S42.
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98.
3. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625-1660.
4. Jaber MA, Al-Remawi MM, Al-Akayleh FT, Al-Kaaisi MS. Formulation and optimization of fast-dissolving tablets of repaglinide using solid dispersion technology. AAPS PharmSciTech. 2021;22(4):142.
5. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70(3):269-277.
6. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. Polymers for mucoadhesive drug delivery system: a review. Drug Dev Ind Pharm. 2008;34(11):1246-1266.
7. Chowdary KP, Rao YS. Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull. 2004;27(11):1717-1724.
8. Shaikh R, Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011;3(1):89-100.
9. Singh B, Raza K, Beg S. Developing "optimized" drug delivery systems using systematic design of experiments. Crit Rev Ther Drug Carrier Syst. 2013;30(6):465-506.
10. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 8th ed. Philadelphia: Wolters Kluwer; 2023.
11. Carr RL. Evaluating flow properties of solids. Chem Eng. 1965;72:163-168.
12. Allen T. Particle Size Measurement. 5th ed. London: Chapman & Hall; 1997.
13. Ramteke KH, Jadhav VB, Kulkarni NS. Formulation and evaluation of mucoadhesive microspheres of glipizide. Int J Pharm Res. 2012;4(2):62-68.
14. United States Pharmacopeia and National Formulary (USP 46-NF 41). Rockville, MD: United States Pharmacopeial Convention; 2023.
15. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-133.